成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 136083-57-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 136083-57-3
Chemical Structure| 136083-57-3
Structure of 136083-57-3 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 136083-57-3 ]

Related Doc. of [ 136083-57-3 ]

Alternatived Products of [ 136083-57-3 ]
Product Citations

Product Citations

Jiang, Hanjie ; Miller, Bryant D ; Viennet, Thibault , et al. DOI: PubMed ID:

Abstract: Lys ubiquitination is catalysed by and is central to the regulation of stability and cell signalling in normal and disease states. There are gaps in our understanding of E3 mechanisms, and here we use semisynthesis, chemical rescue, microscale thermophoresis and other biochemical approaches to dissect the role of catalytic base/acid function and conformational interconversion in HECT-domain E3 catalysis. We demonstrate that there is plasticity in the use of the terminal side chain or backbone carboxylate for proton transfer in HECT reactions, with yeast Rsp5 orthologues appearing to be possible evolutionary intermediates. We also show that the HECT-domain covalent intermediate appears to eject the E2 conjugating enzyme, promoting catalytic turnover. These fndings provide key mechanistic insights into how ubiquitination occurs and provide a framework for understanding E3 functions and regulation.

Purchased from AmBeed: ; ; ;

Product Details of [ 136083-57-3 ]

CAS No. :136083-57-3 MDL No. :MFCD01318740
Formula : C19H17NO6 Boiling Point : No data available
Linear Structure Formula :C15H10O2C4H7NO4 InChI Key :KSDTXRUIZMTBNV-MRXNPFEDSA-N
M.W : 355.34 Pubchem ID :7006674
Synonyms :

Calculated chemistry of [ 136083-57-3 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 26
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.21
Num. rotatable bonds : 8
Num. H-bond acceptors : 6.0
Num. H-bond donors : 3.0
Molar Refractivity : 91.75
TPSA : 112.93 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.91 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.59
Log Po/w (XLOGP3) : 2.19
Log Po/w (WLOGP) : 2.45
Log Po/w (MLOGP) : 1.68
Log Po/w (SILICOS-IT) : 1.88
Consensus Log Po/w : 1.96

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -3.24
Solubility : 0.206 mg/ml ; 0.00058 mol/l
Class : Soluble
Log S (Ali) : -4.2
Solubility : 0.0227 mg/ml ; 0.0000638 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.26
Solubility : 0.0196 mg/ml ; 0.0000551 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 3.8

Safety of [ 136083-57-3 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P305+P351+P338 UN#:
Hazard Statements:H302-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 136083-57-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 136083-57-3 ]

[ 136083-57-3 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 136083-57-3 ]
  • [ 108-24-7 ]
  • [ 77128-73-5 ]
  • 3-[2-(2-acetylamino-acetylamino)-4-methyl-pentanoylamino]-<i>N</i>-(1-carbamoyl-2-phenyl-ethyl)-<i>N</i>-methyl-succinamic acid [ No CAS ]
  • 2
  • [ 29022-11-5 ]
  • [ 136083-57-3 ]
  • [ 108-24-7 ]
  • [ 105047-45-8 ]
  • [ 77128-73-5 ]
  • (S)-3-((S)-2-{(S)-2-[(2-Acetylamino-acetyl)-methyl-amino]-3-phenyl-propionylamino}-6-amino-hexanoylamino)-succinamic acid [ No CAS ]
  • 3
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 104091-09-0 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 96402-49-2 ]
  • [ 94744-50-0 ]
  • Y-(α-aminoisobutyroyl)-EGTFTSDYSIYLDKKAQRAFVNWLLA-(α-aminoisobutyroyl)-KYG-(β-(1-naphthyl)-alaninoyl)-LDF-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Solid phase peptide synthesis was performed on a CEM Liberty Peptide Synthesizer using standard Fmoc chemistry. TentaGel S Ram resin (1 g; 0.25 mmol/g) was swelled in NMP (10 ml) prior to use and transferred between tube and reaction vessel using DCM and NMP. Coupling (0148) An Fmoc-amino acid in NMP/DMF/DCM (1:1:1; 0.2 M; 5 ml) was added to the resin in a CEM Discover microwave unit together with HATU/DMF or COMU/DMF (0.5 M; 2 ml) and DIPEA/NMP (2.0 M; 1 ml). The coupling mixture was heated to 75° C. for 5 min while nitrogen was bubbled through the mixture. The resin was then washed with NMP (4×10 ml). Deprotection (0149) Piperidine/DMF (20percent; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwaves (30 sec; 40° C.). The reaction vessel was drained and a second portion of piperidine/NMP (20percent; 10 ml) was added and heated (75° C.; 3 min.) again. The resin was then washed with DMF (6×10 ml). Side Chain Acylation (0150) Fmoc-Lys(ivDde)-OH or alternatively another amino acid with an orthogonal side chain protective group was introduced at the position of the acylation. The N-terminal of the peptide backbone was then Boc-protected using Boc2O or alternatively by using a Boc-protected amino acid in the last coupling. While the peptide was still attached to the resin, the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4percent) in NMP for 2×15 min. The unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu or another spacer amino acid, which was deprotected with piperidine and acylated with a lipophilic moiety using the peptide coupling methodology as described above. Alternatively, the acylation moiety was introduced as a premade building block e.g. Fmoc-Lys(hexadecanoyl-gamma-Glu)-OH where gamm-Glu is the coupling of Glutamic acid through the side-chain. Abbreviations employed are as follows: COMU: 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholinomethylene)]methanaminium hexaflourophosphate ivDde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl DCM: dichloromethane DMF: N,N-dimethylformamide (0151) DIPEA: diisopropylethylamine EtOH: ethanol Et2O: diethyl ether HATU: N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide MeCN: acetonitrile NMP: N-methylpyrrolidone (0152) TFA: trifluoroacetic acid TIS: triisopropylsilane Cleavage (0153) The resin was washed with EtOH (3×10 ml) and Et2O (3×10 ml) and dried to constant weight at room temperature (r.t.). The crude peptide was cleaved from the resin by treatment with TFA/TIS/water (95/2.5/2.5; 40 ml, 2 h; r.t.). Most of the TFA was removed at reduced pressure and the crude peptide was precipitated and washed three times with diethylether and dried to constant weight at room temperature. HPLC Purification of the Crude Peptide (0154) The crude peptide was purified to greater than 90percent by preparative reverse phase HPLC using a PerSeptive Biosystems VISION Workstation equipped with a C-18 column (5 cm; 10 mum) and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1percent TFA, aq.) and buffer B (0.1percent TFA, 90percent MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. (0155) The synthesized compounds are shown in Table 1 and Table 2
  • 4
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 96402-49-2 ]
  • [ 135248-89-4 ]
  • [ 116611-64-4 ]
  • Hy-CAD-[1-Nal]-VCYWHTFG-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Peptide monomers of the present invention were synthesized using the Merrifield solid phase synthesis techniques on Protein Technology's Symphony multiple channel synthesizer. The peptides were assembled using HBTU (0-Benzotriazole-N,N,N',N'-tetramethyl-uronium- hexafluoro-phosphate), Diisopropylethylamine(DIEA) coupling conditions. For some amino acid couplings PyAOP(7-Azabenzotriazol- 1 -yloxy)tripyrrolidinophosponium hexafluorophosphate) and DIEA conditions were used. Rink Amide MB HA resin (100-200 mesh, 0.57 mmol/g) was used for peptide with C-terminal amides and pre-loaded Wang Resin with N-a-Fmoc protected amino acid was used for peptide with C-terminal acids. The coupling reagents (HBTU and DIEA premixed) were prepared at lOOmmol concentration. Similarly amino acids solutions were prepared at 100 mmol concentration. Peptide inhibitors of the present invention were identified based on medical chemistry optimization and/or phage display and screened to identify those having superior binding and/or inhibitory properties.[00611] The peptides were assembled using standard Symphony protocols. The peptide sequences were assembled as follows: Resin (250 mg, 0.14 mmol) in each reaction vial was washed twice with 4ml of DMF followed by treatment with 2.5ml of 20percent 4-methyl piped dine (Fmoc de- protection) for lOmin. The resin was then filtered and washed two times with DMF (4ml) and re -treated with N-methyl piperifine for additional 30 minute. The resin was again washed three times with DMF (4 ml) followed by addition 2.5ml of amino acid and 2.5ml of HBTU-DIEA mixture. After 45min of frequent agitations, the resin was filtered and washed three timed with DMF (4 ml each). For a typical peptide of the present invention, double couplings were performed. After completing the coupling reaction, the resin was washed three times with DMF (4 ml each) before proceeding to the next amino acid coupling.
  • 5
  • [ 68858-20-8 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 96402-49-2 ]
  • [ 135248-89-4 ]
  • [ 116611-64-4 ]
  • Hy-CADWVCY-[1-NaI]-HTF-OH [ No CAS ]
YieldReaction ConditionsOperation in experiment
Peptide monomers of the present invention were synthesized using the Merrifield solid phase synthesis techniques on Protein Technology's Symphony multiple channel synthesizer. The peptides were assembled using HBTU (0-Benzotriazole-N,N,N',N'-tetramethyl-uronium- hexafluoro-phosphate), Diisopropylethylamine(DIEA) coupling conditions. For some amino acid couplings PyAOP(7-Azabenzotriazol- 1 -yloxy)tripyrrolidinophosponium hexafluorophosphate) and DIEA conditions were used. Rink Amide MB HA resin (100-200 mesh, 0.57 mmol/g) was used for peptide with C-terminal amides and pre-loaded Wang Resin with N-a-Fmoc protected amino acid was used for peptide with C-terminal acids. The coupling reagents (HBTU and DIEA premixed) were prepared at lOOmmol concentration. Similarly amino acids solutions were prepared at 100 mmol concentration. Peptide inhibitors of the present invention were identified based on medical chemistry optimization and/or phage display and screened to identify those having superior binding and/or inhibitory properties.[00611] The peptides were assembled using standard Symphony protocols. The peptide sequences were assembled as follows: Resin (250 mg, 0.14 mmol) in each reaction vial was washed twice with 4ml of DMF followed by treatment with 2.5ml of 20percent 4-methyl piped dine (Fmoc de- protection) for lOmin. The resin was then filtered and washed two times with DMF (4ml) and re -treated with N-methyl piperifine for additional 30 minute. The resin was again washed three times with DMF (4 ml) followed by addition 2.5ml of amino acid and 2.5ml of HBTU-DIEA mixture. After 45min of frequent agitations, the resin was filtered and washed three timed with DMF (4 ml each). For a typical peptide of the present invention, double couplings were performed. After completing the coupling reaction, the resin was washed three times with DMF (4 ml each) before proceeding to the next amino acid coupling.
  • 6
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 104091-09-0 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 77128-73-5 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • C150H228N40O45 [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: tGLP-1 and its analogues 2?13 were all synthesized using general solid-phase peptide synthesis of N-Fmoc/tBu chemistry. 63Fmoc Rink Amide-MBHA resin (0.1 mmol) was added to a 25 ml peptide synthetic vessel and swollen with DMF for 40 min. After deprotected by 25percent piperidine in DMF, a solution of Fmoc-AA-OH (0.4 mmol), HATU (0.4 mmol), HoAt (0.4 mmol) and DIPEA (0.8 mmol) in DMF was added to the vessel. After reacted for 1 h, the resin was washed three times with DMF and three times with CH2Cl2, then qualitative ninhydrin testing was performed to monitor whether some free amino groups still existed on the resin ornot. If not, the resin was washed three times with DMF again and repeated the procedures of deprotection and coupling. Forthe coupling of some unnatural amino acids, NMM instead of DIPEA and NMP instead of DMF were used. Besides, the reaction time was prolonged to 4 h. Following the final deprotection of N-terminus, the target peptide was cleaved from resin with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5) for 2 h atroom temperature. After filtration, the residue solution was concentrated, precipitated with cold diethyl ether and centrifuged for three times. The residue was dissolved in water and purified by Waters 2545 preparative RP-HPLC system. Sephadex G-25 was used for the further purification to remove some short peptide impurities. The molecular mass of the target peptide was confirmed by MALDI-TOF. The purity of peptide was tested with analytical RP-HPLC, and the conditions were as follows: a linear gradient of 20percent mobile phase A and 80percent mobile phase B to 80percent mobile phase A and 20percent mobile phase B (A: acetonitrile containing 0.1percent TFA; B: H2O containing 0.1percent TFA) in 30 min, at a flow rate of 1 mL/minute with UV detection at 214 nm.
  • 7
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 116611-64-4 ]
  • [ 193954-26-6 ]
  • C150H228N40O45 [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: tGLP-1 and its analogues 2-13 were all synthesized using general solid-phase peptide synthesis of N-Fmoc/tBu chemistry. 63Fmoc Rink Amide-MBHA resin (0.1 mmol) was added to a 25 ml peptide synthetic vessel and swollen with DMF for 40 min. After deprotected by 25% piperidine in DMF, a solution of Fmoc-AA-OH (0.4 mmol), HATU (0.4 mmol), HoAt (0.4 mmol) and DIPEA (0.8 mmol) in DMF was added to the vessel. After reacted for 1 h, the resin was washed three times with DMF and three times with CH2Cl2, then qualitative ninhydrin testing was performed to monitor whether some free amino groups still existed on the resin ornot. If not, the resin was washed three times with DMF again and repeated the procedures of deprotection and coupling. Forthe coupling of some unnatural amino acids, NMM instead of DIPEA and NMP instead of DMF were used. Besides, the reaction time was prolonged to 4 h. Following the final deprotection of N-terminus, the target peptide was cleaved from resin with Reagent K (TFA/thioanisole/water/phenol/EDT, 82.5:5:5:5:2.5) for 2 h atroom temperature. After filtration, the residue solution was concentrated, precipitated with cold diethyl ether and centrifuged for three times. The residue was dissolved in water and purified by Waters 2545 preparative RP-HPLC system. Sephadex G-25 was used for the further purification to remove some short peptide impurities. The molecular mass of the target peptide was confirmed by MALDI-TOF. The purity of peptide was tested with analytical RP-HPLC, and the conditions were as follows: a linear gradient of 20% mobile phase A and 80% mobile phase B to 80% mobile phase A and 20% mobile phase B (A: acetonitrile containing 0.1% TFA; B: H2O containing 0.1% TFA) in 30 min, at a flow rate of 1 mL/minute with UV detection at 214 nm.
  • 8
  • [ 250695-67-1 ]
  • [ 35661-60-0 ]
  • [ 112883-29-1 ]
  • [ 136083-57-3 ]
  • [ 35737-15-6 ]
  • [ 35661-38-2 ]
  • [ 73724-45-5 ]
  • [ 125238-99-5 ]
  • C71H111N21O18 [ No CAS ]
YieldReaction ConditionsOperation in experiment
1. Peptide synthesis 1.1 General synthetic procedures A general method for the synthesis of the peptidomimetics of the present invention is exemplified in the following. This is to demonstrate the principal concept and does not limit or restrict the present invention in any way. A person skilled in the art is easily able to modify these procedures, especially, but not limited to, choosing a different starting position within the ring system, to still achieve the preparation of the claimed cyclic peptidomimetic compounds of the present invention. Coupling of the first protected amino acid residue to the resin . In a dried flask, 2-chlorotritylchloride resin (polystyrene, 1percent crosslinked; loading: 1.4 mMol/g) was swollen in dry CH2CI2 for 30 min (7 mL CH2CI2 per g resin). A solution of 0.8 eq of the Fmoc-protected amino acid and 6 eq of DIPEA in dry CH2CI2/DMF (4/1) (10 mL per g resin) was added. After shaking for 2-4 h at rt the resin was filtered off and washed successively with CH2CI2, DMF, CH2CI2, DMF and CH2CI2. Then a solution of dry CH2CI2/MeOH/DIPEA (17:2:1) was added (10 mL per g resin). After shaking for 3 x 30 min the resin was filtered off in a pre-weighed sinter funnel and washed successively with CH2CI2, DMF, CH2CI2, MeOH, CH2CI2, MeOH, CH2CI2 (2x) and Et20 (2x). The resin was dried under high vacuum overnight. The final mass of resin was calculated before the qualitative control. Loading was typically 0.6 - 0.7 mMol/g. The following preloaded resins were prepared: Fmoc-Dab(Boc)-2-chlorotrityl resin, Fmoc-DDab(Boc)-2-chlorotrityl resin, Fmoc-Lys(Boc)-2-chlorotrityl resin, Fmoc- Trp(Boc)-2-chlortrityl resin, Fmoc-Phe-2-chlortrityl resin; Fmoc-Val-2-chlorotrityl resin, Fmoc-Pro-2-chlorotrityl resin, Fmoc-Arg(Pbf)-2-chlorotrityl resin and Fmoc-Glu(iBu)-2- chlorotrityl resin. Synthesis of the fully protected peptide fragment The synthesis was carried out on a Syro-peptide synthesizer (MultiSynTech GmbH) using 24 to 96 reaction vessels. In each vessel 0.04 mMol of the above resin were placed and the resin was swelled in CH2CI2 and DMF for 15 min, respectively. The following reaction cycles were programmed and carried out: Step Reagent Time 1 CH2CI2, wash and swell (manual) 1 x 3 min 2 DMF, wash and swell 2 x 30 min 3 20percent piperidine/DMF 1 x 5 min and 1 x 15 min 4 DMF, wash 5 x 1 min 5 3.5 eq Fmoc amino acid/3.5 eq HOAt in DMF + 3.5 eq PyBOP/7 eq DIPEA or 3.5 eq DIC 1 x 40 min 6 3.5 eq Fmoc amino acid/DMF + 3.5 eq HATU or PyBOP or HCTU + 7 eq DIPEA 1 x 40 min 7 DMF, wash 5 x 1 min 8 20percent piperidine/DMF 1 x 5 min and 1 x 15 min 9 DMF, wash 5 x 1 min 10 CH2CI2, wash (at the end of the synthesis) 3 x 1 min Steps 5 to 9 are repeated to add each amino-acid residue. After the termination of the synthesis of the fully protected peptide fragment, one of the procedures A - E, as described herein below, was adopted subsequently, depending on which kind of interstrand linkages, as described herein below, were to be formed. Finally, the peptides were purified by preparative reverse phase LC-MS, as described herein below. Procedure A: Cyclization and work up of a backbone cyclized peptide having no interstrand linkage Cleavage, backbone cyclization and deprotection After assembly of the linear peptide, the resin was suspended in 1 mL of 1percent TFA in CH2CI2 (v/v; 0.14 mMol) for 3 minutes. After filtration the filtrate was neutralized with 1 mL of 20percent DI PEA in CH2CI2 (v/v; 1.15 mMol). This procedure was repeated four times to ensure completion of the cleavage. An alternative cleavage method comprises suspension of the resin in lmL of 20percent HFIP in CH2CI2 (v/v; 1.9 mMol) for 30 minutes, filtration and repetition of the procedure. The resin was washed three times with 1 mL of CH2CI2. The CH2CI2 layers containing product were evaporated to dryness. The fully protected linear peptide was solubilised in 8 mL of dry DM F. Then 2 eq of HATU and 2 eq of HOAt in dry DM F (1-2 mL) and 4 eq of DIPEA in dry DM F (1-2 mL) were added to the peptide, followed by stirring for ca. 16 h. The volatiles were removed by evaporation. The crude cyclic peptide was dissolved in 7 mL of CH2CI2 and washed three times with 4.5 mL 10percent acetonitrile in water (v/v). The CH2CI2 layer was then evaporated to dryness. To fully deprotect the peptide, 7 mL of cleavage cocktail TFA/DODT/thioanisol/H20 (87.5 :2.5:5:5) or TFA/TIS/H20 (95:2.5 :2.5) were added, and the mixture was kept for 2.5-4 h at room temperature until the reaction was completed. The reaction mixture was evaporated close to dryness, the peptide precipitated with 7 mL of cold Et20/pentane and finally washed 3 times with 4 mL of cold Et20/pentane. Procedures Bl and B2: Cyclization and work up of a backbone cyclized peptide having a disulfide interstrand linkage Bl: Formation of a disulfide interstrand linkage using DMSO After cleavage, backbone cyclization and deprotection of the linear peptide, as described in the corresponding section of procedure A, th...
  • 9
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 136083-57-3 ]
  • [ 71989-23-6 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 75-36-5 ]
  • [ 198561-07-8 ]
  • C48H81N18O14Pol [ No CAS ]
  • 10
  • [ 27243-15-8 ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 112883-29-1 ]
  • [ 71989-31-6 ]
  • [ 136083-57-3 ]
  • [ 73731-37-0 ]
  • [ 135248-89-4 ]
  • [ 116611-64-4 ]
  • N-Fmoc-tyrosine [ No CAS ]
  • C79H101ClN18O25S2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
General procedure: Macrocycles were chemically synthesized using a Syro Wave automated peptide synthesizer (Biotage, Charlotte, NC) by Fmoc solid-phase peptide synthesis as previously described (Morimoto et al., Angew Chem. Int. Ed. Engl.51:3423-3427, 2012; Yamagata et al., Structure 22:345-352, 2012). Briefly, the chloroacetyl group or acetyl group was coupled onto the N-terminal amide group for the formation of cyclic or linear peptide analogs respectively after the automated synthesis. Peptides were cleaved by a solution of 92.5%trifluoroacetic acid (TFA), 2.5% water, 2.5% triisopropylsilane, and 2.5% ethanedithiol and precipitated by diethyl ether. To conduct the cyclization reaction, peptide pellet was dissolved in 10 mL DMSO/0.1%TFA in water (1:1), adjusted the pH>8 by addition of triethylamine and incubated for 1 h at 25C. This cyclization reaction was quenched by addition of TFA to acidify the peptide suspensions. Then peptides were purified by reverse-phase HPLC (RP-HPLC) and molecular masses were verified by MALDI-TOF mass spectrometry, using a microflex or ultraflex instrument (Bruker Daltonics, Billerica, MA) (FIG.5 and Table 2).All peptides were chemically synthesized on a 25 mumole scale using a Syro Wave automated peptide synthesizer (Biotage) by Fmoc solid phase peptide chemical synthesis (SPPS). Firstly, ^ ^ ^ ^ NovaPEG Rink Amide resins were incubated with N,N-dimethylformamide (DMF) with rotation at ambient temperature for 30 min and washed 5 times with DMF. Coupling of each Fmoc-protected amino acid was performed on the engorged resin with a solution of 300 muL 0.5 M Fmoc-protected amino acid, 300 muL 0.5 M 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and 1-hydroxybenzotriazole (HOBt), and 150 muL 0.5 M N,N-diisopropylethylamine (DIPEA) in DMF and reacted for 1 hour at ambient temperature. After washing the resins with 1 mL DMF five times, Fmoc-deprotection was performed by incubating the resin with 600 muL 40% piperidine in DMF (vol/vol) and reacted for 30 min at ambient temperature. Each peptide was synthesized using the appropriately protected amino acid monomers corresponding to sequences in Tables 6 and 8 by repeating the Fmoc-protected amino acid coupling and Fmoc-deprotection steps accordingly. The N- terminal alpha-amino group of the synthesized peptides on the resin was chloroacetylated by incubating with a solution of 500 muL 0.5 M chloroacetyl N-hydroxysuccinimide (NHS) ester in N- methylpyrrolidone (NMP) with rotation for 60 min at ambient temperature. For the synthesis of Ce-L2 and Ce-L2d, the N-terminal alpha-amino group was acetylated by incubating with a solution of 500 muL 0.5 M acetic anhydride and 0.25 M DIPEA in NMP with rotation for 60 min at ambient temperature. After washing the resin with 5 x 1 mL DMF, peptides were fully deprotected and cleaved from resin by incubating with a solution of 2 mL trifluoroacetic acid (TFA), water, triisopropylsilane (TIS) and ethanedithiol (EDT) (92.5:2.5:2.5:2.5) with rotation for 3 hours at ambient temperature andprecipitated with diethyl ether. The peptide pellet was dissolved in 10 mL DMSO/0.1%TFA in water (1:1), and the pH adjusted to >8 by addition of triethylamine (TEA), and incubated at ambient temperature for 1 h to enhance the cyclization via a thioether bond formation between N-terminal chloroacetamide group and cysteine sulfhydryl group. Peptide mass and cyclization was confirmed by MALDI-TOF MS analysis. The cyclization reaction was quenched by addition of TFA to acidify the peptide suspensions. Peptides were then purified by reverse-phase HPLC (Table 4), molecular masses were verified by MALDI-TOF MS analysis (Table 4), using a microflex or autoflex instrument (Bruker Daltonics). Ring junction confirmed by MSMS spectrum and fragment analysis (FIG.5).
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 136083-57-3 ]

Amino Acid Derivatives

Chemical Structure| 145038-52-4

[ 145038-52-4 ]

Fmoc-Asp-OMe

Similarity: 0.97

Chemical Structure| 368443-82-7

[ 368443-82-7 ]

Fmoc-D-Asp-OMe

Similarity: 0.97

Chemical Structure| 146549-21-5

[ 146549-21-5 ]

Fmoc-Gly(allyl)-OH

Similarity: 0.97

Chemical Structure| 174879-28-8

[ 174879-28-8 ]

2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)butanoic acid

Similarity: 0.97

Chemical Structure| 170642-27-0

[ 170642-27-0 ]

Fmoc-D-Abu-OH

Similarity: 0.97

; ;